Ischemic Heart Disease
Conditions
Brief summary
This is a six (6) month, randomized, un-blinded, study to assess the safety and performance of the Palmaz Mach-5 Grooved Coronary Stent System vs. the Palmaz Bare Metal Coronary Stent System.
Interventions
DEVICEcoronary stent
Sponsors
ClinLogix. LLC
Palmaz Scientific
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients of any race greater than or equal to 18 years and of legal consent 2. Patients must be willing to comply with the specified follow-up evaluation schedule 3. Patients who sign an informed consent (signed and dated) prior to any study-related evaluation or procedure. 4. Patients who are willing to undergo a follow-up coronary angiogram and Endovascular Imaging via Optical Coherence Tomography 5. Patients willing to be maintained on Aspirin and Clopidogrel bisulfate (Plavix) for ninety (90) days post procedure. 6. Patients with a de novo coronary lesion causing angina and/or a positive function test 7. Patients who are eligible for percutaneous coronary interventions 8. Low risk NSTEMI defined as patients with ACS, unstable angina, positive cardiac biomarkers and hemodynamically stable as assessed by the Investigator. 9. Patients with an acceptable risk for coronary bypass graft surgery (CABG) Intra-Procedure Angiographic Criteria: 1. Single de novo target lesion \>50% diameter stenosis by angiography 2. Single target vessel 2.75 to 3.25 mm diameter 3. Lesion length of 14 to 20mm which is suitable for Palmaz Mach-5 Grooved Coronary Stent System or the Palmaz Bare Metal Coronary Stent System.
Exclusion criteria
1. Known allergy or sensitivity to cobalt chromium (CoCr) alloy or its components. 2. Known sensitivity or allergy to aspirin, radiographic contract agents (that cannot be pre-treated adequately). 3. Patients unable to tolerate anticoagulant therapy or antiplatelet therapy. 4. History of bleeding or known coagulopathy. 5. Patients with thrombocytopenia and or neutropenia. 6. More than one stenosis \>50% in target vessel. 7. Lesion in aortic ostium. 8. Left main or LAD, CX lesions within 2-mm from the origin. 9. Ejection Fraction \<45%. 10. STEMI in evolution. 11. Disabling stroke within previous 30 days. 12. Patients currently enrolled in another Investigational device or drug study. 13. Previous enrollment in this study. 14. Women who are currently pregnant. (A negative pregnancy test for female subjects of child bearing potential is required within 24 hours of procedure.) 15. Known or suspected active systemic infection. 16. Evidence of severe or uncontrolled systemic diseases, including chronic renal insufficiency, or any condition which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| late lumen loss rate by Quantative/ Qualtative Cornary Angiographia | 6 month |
| total percentage of strut coverage by Optical Coherence Tomography analysis | 6 month |
| Primary safety endpoint is the occurrence of adverse events associated with the Investigational and comparator devices. | 6 month |
| binary restenosis rate by Quantative/ Qualtative Cornary Angiographia | 6 month |
Outcome results
None listed